AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33964856 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure adolescent girls aged 14-18 years
Number of subjects: 9147
Study 33964856 — intervention group
Group type: COMPARATOR
Intervention: Food-secure adolescent girls
Number of subjects: 9147
Study 33964856 — intervention group
Group type: COMPARATOR
Intervention: Food-insecure adolescent girls
Number of subjects: 9147
Study 33964856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diet quality
Number of subjects: 9147
Study 33964867 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric ultrasound assessment
Number of subjects: 45
Study 33964917 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with mental health services (measured by Client Satisfaction Questionnaire-8)
Number of subjects: 292
Study 33964917 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived support for personal recovery
Number of subjects: 292
Study 33964917 — intervention group
Group type: COMPARATOR
Intervention: Community Treatment Order (CTO) status
Number of subjects: 292
Study 33964917 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and personal recovery
Number of subjects: 292
Study 33964942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated irradiation (5 × 2 Gy/week for 3-5 weeks)
Number of subjects: 0
Study 33964942 — intervention group
Group type: COMPARATOR
Intervention: Blocking interferon-beta and/or -lambda
Number of subjects: 0
Study 33964942 — intervention group
Group type: COMPARATOR
Intervention: Targeted inhibition of STING protein
Number of subjects: 0
Study 33964942 — intervention group
Group type: COMPARATOR
Intervention: Knockout of STING expression
Number of subjects: 0
Study 33965000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor (100 mg-125 mg every 12 h for <14 kg, 150 mg-188 mg for ≥14 kg, 200 mg-250 mg for ≥6 years)
Number of subjects: 60
Study 33965000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 60
Study 33965006 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment scale-up (12 weeks of sofosbuvir plus velpatasvir)
Number of subjects: 1643
Study 33965006 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment scale-up
Number of subjects: 1643
Study 33965236 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSF (Neupogen) at 5 μg/kg
Number of subjects: 16
Study 33965236 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSF (Neupogen) at 10 μg/kg
Number of subjects: 16
Study 33965236 — intervention group
Group type: COMPARATOR
Intervention: No GCSF (control group)
Number of subjects: 16
Study 33965384 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS1 immunofluorescence (IF) staining
Number of subjects: 240
Study 33965384 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap staining
Number of subjects: 240
Study 33965594 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 33966020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 964
Study 33966020 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 964
Study 33966020 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/ARB
Number of subjects: 964
Study 33966020 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitherapy
Number of subjects: 964
Study 33966020 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT)
Number of subjects: 964
Study 33966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 53
Study 33966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with methotrexate with or without rituximab
Number of subjects: 53
Study 33966128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG) combined with intravenous pembrolizumab
Number of subjects: 13
Study 33966452 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-5074
Number of subjects: 0
Study 33966452 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33966491 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus plus 2-hour infusion)
Number of subjects: 227
Study 33966493 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin doses (33 to 165 μMol)
Number of subjects: 30
Study 33966568 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid infusion with rapid once-daily weaning, especially rate reduction more than 50 µg as fentanyl equivalent per hour
Number of subjects: 55
Study 33966568 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid infusion with rapid once-daily weaning
Number of subjects: 55
Study 33966568 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid infusion
Number of subjects: 55
Study 33966568 — intervention group
Group type: COMPARATOR
Intervention: Non-withdrawal group
Number of subjects: 55
Study 33966635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) with feature tracking analysis for RV global longitudinal strain assessment (RV GLS)
Number of subjects: 27
Study 33966635 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-FDG positron emission tomography (PET) analysis for RV glucose uptake
Number of subjects: 27
Study 33966635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CMR and hemodynamic measurements
Number of subjects: 27
Study 33966635 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 controls)
Number of subjects: 27
Study 33966886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 262
Study 33966886 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 262
Study 33966954 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care phase of a multi-site quasi-experimental study
Number of subjects: 148
Study 33967195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles (and up to eight cycles).
Number of subjects: 102
Study 33967246 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive image-guided left cochlear implantation (CI)
Number of subjects: 1
Study 33967246 — intervention group
Group type: COMPARATOR
Intervention: Traditional cochlear implantation
Number of subjects: 1
Study 33967683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gait training with electromechanical assistance
Number of subjects: 0
Study 33967683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gait training without electromechanical assistance
Number of subjects: 0
Study 33967683 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33968064 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 76
Study 33968064 — intervention group
Group type: COMPARATOR
Intervention: Late antiretroviral therapy (ART)
Number of subjects: 76
Study 33968735 — intervention group
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Number of subjects: 0
Study 33968845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular pharmacological support
Number of subjects: 0
Study 33968949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum Torque Teno Virus Load
Number of subjects: 0
Study 33969012 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-CT-based quantification of extracted thrombus burden characteristics
Number of subjects: 0
Study 33969423 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Sleepers
Number of subjects: 125
Study 33969423 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Sleepers
Number of subjects: 125
Study 33969456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5-10 mg, multiple doses; 10 mg, single dose)
Number of subjects: 0
Study 33969456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 33969578 — intervention group
Group type: EXPERIMENTAL
Intervention: IM + 2 incisions
Number of subjects: 805
Study 33969578 — intervention group
Group type: COMPARATOR
Intervention: SC + 2 incisions
Number of subjects: 805
Study 33969578 — intervention group
Group type: COMPARATOR
Intervention: SC + 3 incisions
Number of subjects: 805
Study 33969578 — intervention group
Group type: COMPARATOR
Intervention: IM + 3 incisions
Number of subjects: 805
Study 33970027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4K High-Definition System in Laparoscopic Gastrectomy
Number of subjects: 0
Study 33970109 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized haptic feedback (vibrations) provided after 30 minutes of uninterrupted sitting
Number of subjects: 26
Study 33970109 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized haptic feedback provided between noon and 3 PM
Number of subjects: 26
Study 33970392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HER2 and ER biomarkers, %HbT at the end of cycle 1 (EOC1), and %US (EOC1)
Number of subjects: 41
Study 33970392 — intervention group
Group type: EXPERIMENTAL
Intervention: %US (EOC1) and %HbT (EOC1) independent of HER2 and ER status
Number of subjects: 41
Study 33970392 — intervention group
Group type: EXPERIMENTAL
Intervention: %US at EOC1 and %HbT (EOC3) independent of biomarker status
Number of subjects: 41
Study 33970454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 33970454 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 0
Study 33970687 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib
Number of subjects: 46
Study 33970864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise plus Chinese herbal medicines
Number of subjects: 172
Study 33970864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise only
Number of subjects: 172
Study 33970864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines only
Number of subjects: 172
Study 33970864 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (receiving Chinese herbal medicines after 24 weeks)
Number of subjects: 172
Study 33971009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix; GSK) during pregnancy
Number of subjects: 0
Study 33971036 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak atrial longitudinal strain (PALS) measurement in patients with COPD
Number of subjects: 175
Study 33971036 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS as a predictor of atrial fibrillation (AF)
Number of subjects: 175
Study 33971036 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS cutoff value for predicting AF
Number of subjects: 175
Study 33971036 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of AF events in COPD patients
Number of subjects: 175
Study 33971070 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER)
Number of subjects: 0
Study 33971168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 140
Study 33971168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 140
Study 33971185 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-based decisions
Number of subjects: 334
Study 33971185 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive functional assessment
Number of subjects: 334
Study 33971185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Number of subjects: 334
Study 33971185 — intervention group
Group type: COMPARATOR
Intervention: Comparison to ISIS-1
Number of subjects: 334
Study 33971650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for tetanus
Number of subjects: 306
Study 33971650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for varicella
Number of subjects: 306
Study 33971650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for measles
Number of subjects: 306
Study 33971650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status for various antigens
Number of subjects: 306
Study 33971828 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin pessary
Number of subjects: 58
Study 33971828 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion and close monitoring of the Arabin pessary
Number of subjects: 58
Study 33971856 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg administered subcutaneously
Number of subjects: 145
Study 33971982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Council involvement in the clinical study
Number of subjects: 5
Study 33971982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Council's input to clinical protocol
Number of subjects: 5
Study 33971982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Council's role in dissemination of results and project advocacy
Number of subjects: 5
Study 33971982 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges faced by the Patient Council
Number of subjects: 5
Study 33972002 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm-to-Special Supplemental Nutrition Programme for Women, Infants and Children (WIC) intervention
Number of subjects: 297
Study 33972083 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF pregnancies
Number of subjects: 1347
Study 33972083 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous pregnancies
Number of subjects: 1347
Study 33972315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33972329 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric fracture centres (GFCs)
Number of subjects: 281
Study 33972329 — intervention group
Group type: COMPARATOR
Intervention: Usual care centres (UCCs)
Number of subjects: 281
Study 33972338 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 33972338 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33972949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab (600 mg, n=261)
Number of subjects: 520
Study 33972949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=259)
Number of subjects: 520
Study 33972949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab (600 mg)
Number of subjects: 520
Study 33973108 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L utility index
Number of subjects: 453
Study 33973232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 328
Study 33973232 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alkaline phosphatase and baseline amylase
Number of subjects: 328
Study 33973293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous envafolimab 0.01-10 mg/kg once weekly
Number of subjects: 28
Study 33973293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous envafolimab 300 mg once every 4 weeks
Number of subjects: 28
Study 33973402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline superficial medial femorotibial compartment (MFTC) T2 in progressor knees (adjusted mean 47.2 msec, 95% CI 46.5, 48.0)
Number of subjects: 600
Study 33973402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline superficial medial femorotibial compartment (MFTC) T2 in JSW progression only knees (adjusted mean 47.3 msec, 95% CI 46.3, 48.3)
Number of subjects: 600
Study 33973402 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in deep MFTC T2 between baseline and 12 months
Number of subjects: 600
Study 33973402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline superficial medial cartilage T2
Number of subjects: 600
Study 33973534 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB score at discharge
Number of subjects: 119
Study 33973534 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB score 0-3 at discharge
Number of subjects: 119
Study 33973550 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33973646 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 95
Study 33973646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 95
Study 33973646 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 95
Study 33973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dartmouth PATH Program (self-guided online intervention)
Number of subjects: 562
Study 33973866 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultation
Number of subjects: 140
Study 33973866 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 140
Study 33973868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support program for patients with LEP
Number of subjects: 137
Study 33974038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) using autologous bone marrow CD34+ cells transduced with MND-ADA gammaretroviral vector, infused after busulfan reduced-intensity conditioning.
Number of subjects: 10
Study 33974038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 10
Study 33974216 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR)
Number of subjects: 1214
Study 33974304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk elimination diet (CME)
Number of subjects: 62
Study 33974366 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous ex vivo lentiviral gene therapy
Number of subjects: 50
Study 33974369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of a diffractive-refractive trifocal IOL
Number of subjects: 50
Study 33974372 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6WT)
Number of subjects: 49
Study 33974372 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 49
Study 33974419 — intervention group
Group type: EXPERIMENTAL
Intervention: Skepinone-based p38α MAP kinase inhibitors (methyl ester prodrugs)
Number of subjects: 0
Study 33974419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of urinary EGF
Number of subjects: 865
Study 33974569 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of MCP-1
Number of subjects: 865
Study 33974585 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched Sibling Donor (MSD)
Number of subjects: 45
Study 33974585 — intervention group
Group type: COMPARATOR
Intervention: Matched Unrelated Donor (MUD)
Number of subjects: 45
Study 33974707 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV variants
Number of subjects: 2122
Study 33974707 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA alleles
Number of subjects: 2122
Study 33974707 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV variants and immunotypes
Number of subjects: 2122
Study 33974994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FITs)
Number of subjects: 3600
Study 33974994 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 3600
Study 33975540 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP adherence
Number of subjects: 132
Study 33975557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status (25(OH) D < 50 nmol/L) in rectal cancer patients
Number of subjects: 129
Study 33975557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status in men
Number of subjects: 129
Study 33975557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D status in women
Number of subjects: 129
Study 33975557 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 disease presentation
Number of subjects: 129
Study 33975557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 129
Study 33975597 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown measures
Number of subjects: 2067
Study 33975601 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 963
Study 33975601 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 963
Study 33975601 — intervention group
Group type: EXPERIMENTAL
Intervention: ACME risk factors
Number of subjects: 963
Study 33975601 — intervention group
Group type: COMPARATOR
Intervention: Tokyo Guidelines (TG) classification
Number of subjects: 963
Study 33976135 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resections
Number of subjects: 0
Study 33976135 — intervention group
Group type: COMPARATOR
Intervention: Sputum samples
Number of subjects: 0
Study 33976135 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analysis of Mycobacterium tuberculosis
Number of subjects: 0
Study 33976135 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of genetic diversity
Number of subjects: 0
Study 33976538 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg) combined with FOLFOX4 every two weeks
Number of subjects: 34
Study 33976544 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of CT
Number of subjects: 1221
Study 33976544 — intervention group
Group type: COMPARATOR
Intervention: QCT assessment
Number of subjects: 1221
Study 33976544 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessments from both sets of radiologists
Number of subjects: 1221
Study 33976544 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking and female gender
Number of subjects: 1221
Study 33977224 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care intervention to reverse frailty and enhance resilience through exercise and dietary protein education
Number of subjects: 0
Study 33977387 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III Grade B generalized periodontitis (GP-B)
Number of subjects: 60
Study 33977387 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III Grade C generalized periodontitis (GP-C)
Number of subjects: 60
Study 33977387 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 60
Study 33977415 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS survivors
Number of subjects: 205